DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20200276

Flunarizine: a review of its role in migraine prophylaxis

M. V. Francis, Sumit Singh, Vishal Goyal, Mukundraj Keny

Abstract


Flunarizine, a potent calcium channel blocker has been used for more than three decades for the prophylactic management of migraine. Theories suggest that flunarizine may act through multiple mechanisms such as inhibition of cortical spreading depression, neurogenic inflammation and channelopathy. Flunarizine is efficacious in the management of various types of migraines such as common, classical, vestibular, abdominal, hemiplegic and pediatric migraine. It has a manageable safety profile with weight gain and drowsiness being commonly reported.


Keywords


Calcium channel, Channelopathy, Flunarizine, Hemiplegic, Migraine, Prophylaxis

Full Text:

PDF

References


Burstein R, Noseda R, Borsook D. Migraine: Multiple Processes, Complex Pathophysiology. J Neurosci. 2015;35(17):6619-29.

Kulkarni G, Rao G, Gururaj G, Subbakrishna DK, Steiner T, Stovner LJ. EHMTI-0333. The prevalence and burden of migraine in india: results of a population-based study in Karnataka state. J Headache Pain. 2014;15(Suppl 1):B18.

Ray BK, Paul N, Hazra A, Das S, Ghosal MK, Misra AK, et al. Prevalence, burden, and risk factors of migraine: A community-based study from Eastern India. Neurol India. 2017;65:1280-8.

Francis MV. High prevalence of migraine in women in a south Indian coastal population. Po136. Cephalalgia. 2009;29:64-5.

Migraine prophylaxis: flunarizine. Evidence summary [ESUOM33]; Published date: September 2014. Available at: https://www.nice.org.uk/advice/esuom33/chapter/Key-points-from-the-evidence. Accessed on 9 December 2019.

Gelmers HJ. Calcium-channel blockers in the treatment of migraine. Am J Cardiol. 1985;55:139b-43.

Treatment Guideline Subcommittee of the Taiwan Headache Society. [Treatment guidelines for preventive treatment of migraine]. Acta Neurol Taiwan. 2008;17(2):132-48.

Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16:968-81.

Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39(2 Suppl 2):S1-59.

Tottene A, Conti R, Fabbro A, Vecchia D, Shapovalova M, Santello M, et al. Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice. Neuron. 2009;61:762-73.

Eikermann-Haerter K, Can A, Ayata C. Pharmacological targeting of spreading depression in migraine. Expert Rev Neurother. 2012;12(3):297-306.

Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011;13:e36.

Tajti J, Szok D, Majlath Z, Tuka B, Csati A, Vecsei L. Migraine and neuropeptides. Neuropeptides. 2015;52:19-30.

Hashimoto M, Yamamoto Y, Takagi H. Effects of KB-2796 on plasma extravasation following antidromic trigeminal stimulation in the rat. Res Commun Mol Pathol Pharmacol. 1997;97:79-94.

Bono G, Manzoni GC, Martucci N, Baldrati A, Farina S, Cassabgi F, et al. Flunarizine in common migraine: Italian cooperative trial. II. Long-term follow-up. Cephalalgia. 1985;5:155-158.

Nuti A, Lucetti C, Pavese N, Dell'Agnello G, Rossi G, Bonuccelli U. Long-term follow-up after flunarizine or nimodipine discontinuation in migraine patients. Cephalalgia. 1996;16(5):337-40.

Martinez-Lage JM. Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia. 1988;8:15-20.

Centonze V, Magrone D, Vino M, Caporaletti P, Attolini E, Campanale G, et al. Flunarizine in migraine prophylaxis: efficacy and tolerability of 5 mg and 10 mg dose levels. Cephalalgia. 1990;10:17-24.

Lempert T, Neuhauser H. Epidemiology of vertigo, migraine and vestibular migraine. J Neurol. 2009;256:333-8.

Aydin M, Kabakus N, Bozdag S, Ertugrul S. Profile of children with migraine. Indian J Pediatr. 2010;77:1247-51.

Barnes N, Millman G, James E. Migraine headache in children. Clin Evid. 2005:388-95.

Francis MV. Brief migraine episodes in children and adolescents-a modification to International Headache Society pediatric migraine (without aura) diagnostic criteria. Springer Plus. 2013;2:77.

Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;63:2215-24.

Francis MV. Episodic Syndromes That May Be Associated with Migraine-Two Clinically Useful Markers. J Headache Pain Management. 2016;1:10.

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd Ed. Cephalalgia. 2018;38:1-211.

Leone M, Grazzi L, La Mantia L, Bussone G. Flunarizine in migraine: a minireview. Headache. 1991;31:388-91.

Colucci D'Amato C, Colucci D'Amato A, Alfano V, Giordano E, Marmo E. Flunarizine in long-term migraine prophylaxis: clinical evidence. J Med. 1990;21:201-7.

De Bock G, Eelhart J, Van Marwijk H, Tromp T, Springer M. A postmarketing study of flunarizine in migraine and vertigo. Pharm World Sci. 1997;19(6):269-74.

Diener HC, Holle-Lee D, Nagel S, Dresler T, Gaul C, Gobel H, et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clin Translational Neuroscience. 2019; 1:1–40.

Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain. 2012;13:S31-70.

Bendtsen L, Birk S, Kasch H, Pini LA, Guidetti V, Bono G, et al. Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Ed 2012. J Headache and Pain. 2012;13:1-29.

Migraine prophylaxis: flunarizine. Evidence summary [ESUOM33]; Published date: September 2014. Available at: https://www.nice.org.uk/advice/esuom33/chapter/Key-points-from-the-evidence. Accessed on 9 December 2019.

Clinical Practice Guidelines. Diagnosis and Management of Headache by Ministry of Health, Singapore. 2007. Available at: https://www.moh.gov.sg/docs/librariesprovider4/guidelines/cpg_headache_booklet.pdf Accessed on 9 December 2019.

Ravishankar K, Chakravarty A, Chowdhury D, Shukla R, Singh S. Guidelines on the diagnosis and the current management of headache and related disorders. Ann Indian Acad Neurol. 2011;14:S40-59.

Victor S, Ryan SW. Drugs for preventing migraine headaches in children. Cochrane Database Syst Rev. 2003:Cd002761.

Goadsby PJ. Migraine and Other Primary Headache Disorders. In: Jameson JL, Fauci A, Kasper D, Hauser S, Longo D, Loscalzo J. Harrison's Principles of Internal Medicine. 20th Ed.: McGraw Hill Education Medical; 2018:3096-3108.

Lucking CH, Oestreich W, Schmidt R, Soyka D. Flunarizine vs. propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia. 1988;8:21-6.

Ludin HP. Flunarizine and propranolol in the treatment of migraine. Headache: J Head Face Pain. 1989;29:219-24.

Shimell C, Fritz V, Levien S. A comparative trial of flunarizine and propranolol in the prevention of migraine. S Afr Med J. 1990;77(2):75-7.

Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci. 1992;19:340-5.

Bordini CA, Arruda MA, Ciciarelli MC, Speciali JG. Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arquivos de neuro-psiquiatria. 1997;55:536-41.

Diener HC, Matias-Guiu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002;22:209-21.

Luo N, Di W, Zhang A, Wang Y, Ding M, Qi W, et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med. 2012;13:80-6.

Gracia-Naya M, Rios C, García-Gomara M, Sanchez-Valiente S, Mauri-Llerda JA, Santos-Lasaosa S, et al. A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse. Revista de Neurologia. 2013;57:347-53.

Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A. Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial. Eur Arch Otorhinolaryngol. 2014;271:2931-6.

Liu F, Ma T, Che X, Wang Q, Yu S. The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine. Frontiers in Neurol. 2017;8:524.

Visudtibhan A, Lusawat A, Chiemchanya S, Visudhiphan P. Flunarizine for prophylactic treatment of childhood migraine. J Med Assoc Thai. 2004;87:1466-70.

Guidetti V, Moscato D, Ottaviano S, Fiorentino D, Fornara R. Flunarizine and migraine in childhood. Cephalalgia. 1987;7:263-6.

Kim H, Byun SH, Kim JS, Lim BC, Chae JH, Choi J, et al. Comparison of flunarizine and topiramate for the prophylaxis of pediatric migraines. Eur J Paediatr Neurol. 2013;17:45-9.

Peer Mohamed B, Goadsby PJ, Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine. Dev Med Child Neurol. 2012;54:274-7.

Boccia G, Del Giudice E, Crisanti AF, Strisciuglio C, Romano A, Staiano A. Functional gastrointestinal disorders in migrainous children: efficacy of flunarizine. Cephalalgia. 2006;26:1214-9.

Kothare SV. Efficacy of flunarizine in the prophylaxis of cyclical vomiting syndrome and abdominal migraine. Eur J Paediatr Neurol. 2005;9:23-6.

Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen B. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia. 2005;25:1048-53.

Lugaresi A, Montagna P, Gallassi R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. Eur Neurol. 1988;28:208-11.

Abu-Arafeh I. Flunarizine for the prevention of migraine - a new look at an old drug. Dev Med Child Neurol. 2012;54:204-5.

Albani F, Baldrati A, Cortelli P, Riva R, Baruzzi A. Flunarizine plasma concentrations and side effects in migraine patients. Headache. 1990;30:369-70.

Bassi P, Brunati L, Rapuzzi B, Alberti E, Mangoni A. Low dose flunarizine in the prophylaxis of migraine. Headache. 1992;32:390-2.